{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:19:42Z","timestamp":1782170382554,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008341","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T16:17:05Z","timestamp":1263831425000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Golimumab for rheumatoid arthritis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Jasvinder A","family":"Singh","sequence":"first","affiliation":[{"name":"Minneapolis VA Medical Center; Medicine; 1 Veterans Drive Rheumatology (111R) Minneapolis Minnesota USA 55417"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Noorbaloochi","sequence":"additional","affiliation":[{"name":"Minneapolis VA Medical Center and University of Minnesota; Medicine; One Veterans Drive Minneapolis MN USA 55417"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurkirpal","family":"Singh","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine; Division of Gastroenterology and Hepatology; 703 Welch Road, Suite F-5, Palo Alto, CA 94304 Palo Alto CA USA 94304"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD008341-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD008341-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1002\/14651858.CD008341-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9685","key":"10.1002\/14651858.CD008341-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008341-BIB0005|cit5","first-page":"374","article-title":"New data shows golimumab significantly improves signs and symptoms of rheumatoid arthritis","volume":"38","author":"O'Connell","year":"2008","journal-title":"Geriatric Medicine"},{"key":"10.1002\/14651858.CD008341-BIB0006|cit6","first-page":"125","article-title":"Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Oldfield","year":"2009","journal-title":"Bio Drugs"},{"key":"10.1002\/14651858.CD008341-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0738-3991(98)00144-X","article-title":"Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration)","volume":"38","author":"Barlow","year":"1999","journal-title":"Patient Educ Couns"},{"issue":"4","key":"10.1002\/14651858.CD008341-BIB0009|cit9","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"CMAJ"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003785","article-title":"Infliximab for the treatment of rheumatoid arthritis","author":"Blumenauer","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008341-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0889-857X(05)70209-X","article-title":"Rheumatoid arthritis. Treatment of early disease","volume":"27","author":"Boers","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"10.1002\/14651858.CD008341-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1172\/JCI36389","article-title":"Evidence that cytokines play a role in rheumatoid arthritis","volume":"118","author":"Brennan","year":"2008","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1002\/14651858.CD008341-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1002\/14651858.CD008341-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal","volume":"44","author":"Choy","year":"2005","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD008341-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1136\/ard.2005.048975","article-title":"Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities","volume":"65","author":"Chung","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1002\/14651858.CD008341-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.berh.2006.05.011","article-title":"New cytokine targets in inflammatory rheumatic diseases","volume":"20","author":"Connell","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1002\/14651858.CD008341-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Deeks J Higgins J Altman D Chapter 9: Analysing data and undertaking meta-analyses, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008) The Cochrane Collaboration. Available from: www.cochrane-handbook.org. 2008","DOI":"10.1002\/9780470712184.ch9"},{"key":"10.1002\/14651858.CD008341-BIB0018|cit18","unstructured":"FDA SIMPONI\u00ae (Golimumab) Physician Packet Insert: Highlights of Prescribing Information http:\/\/www.accessdata.fda.gov\/drugsatdfa_docs\/label\/2009\/125289s000lbl.pdf 2009"},{"key":"10.1002\/14651858.CD008341-BIB0019|cit19","unstructured":"FDA SIMPONI\u00ae (Golimumab) Summary Review FDA Center for Drug Evaluation and Research http:\/\/www.accessdata.fda.gov\/drugsatdfa_docs\/nda\/2009\/125289s000_SumR.pdf"},{"key":"10.1002\/14651858.CD008341-BIB0020|cit20","unstructured":"FDA Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009 http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm175843.htm"},{"issue":"6","key":"10.1002\/14651858.CD008341-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American college of rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis & Rheumatism"},{"issue":"S39","key":"10.1002\/14651858.CD008341-BIB0022|cit22","first-page":"S93","article-title":"The disease activity score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008341-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD008341-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"18","key":"10.1002\/14651858.CD008341-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis. Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD008341-BIB0026|cit26","article-title":"Chapter 8: Assessing risk of bias in included studies. . In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","volume-title":"www.cochrane-handbook.org","author":"Higgins","year":"2008"},{"issue":"4","key":"10.1002\/14651858.CD008341-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"Karlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1002\/14651858.CD008341-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009740500327727","article-title":"Quality of life in rheumatoid arthritis","volume":"34","author":"Kvien","year":"2005","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1002\/14651858.CD008341-BIB0029|cit29","first-page":"481\u201391","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiologic Diagnosis (Stockholm)"},{"issue":"4","key":"10.1002\/14651858.CD008341-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004525","article-title":"Etanercept for the treatment of rheumatoid arthritis","author":"Lethaby","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008341-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007356","article-title":"Rituximab for rheumatoid arthritis","author":"Lopez-Olivo","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD008341-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007277","article-title":"Abatacept for rheumatoid arthritis","author":"Maxwell","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD008341-BIB0034|cit34","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis","author":"Mertens","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005113.pub2","article-title":"Adalimumab for treating rheumatoid arthritis","author":"Navarro-Sarabia","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008341-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/03009740510018633","article-title":"Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register.","volume":"34","author":"Odegard","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1002\/14651858.CD008341-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrd2982","article-title":"Golimumab","volume":"8","author":"Pappas","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/14651858.CD008341-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008341-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis & Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD008341-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","article-title":"Tumor necrosis factor inhibitors for rheumatoid arthritis","volume":"355","author":"Scott","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD008341-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/ard.2008.105940","article-title":"New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?","volume":"68","author":"Scott","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1002\/14651858.CD008341-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"706\u201320","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.bor.0000265447.48722.04","article-title":"The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence","volume":"19","author":"Siddiqui","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1002\/14651858.CD008341-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","article-title":"Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis","volume":"1","author":"Heijde","year":"1989","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0045|cit45","first-page":"579","article-title":"Development of a disease activity score based on judgment in clinical practice by rheumatologists","volume":"20","author":"Heijde","year":"1993","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD008341-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/art.1780390325","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al","volume":"39","author":"Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"1-2","key":"10.1002\/14651858.CD008341-BIB0047|cit47","first-page":"12","article-title":"The pathogenesis of rheumatoid arthritis","volume":"64","author":"Weissmann","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1002\/14651858.CD008341-BIB0048|cit48","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient's perspective","volume":"20","author":"Wells","year":"1993","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008341-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0140-6736(09)60792-3","article-title":"Treatment of rheumatoid arthritis: we are getting there","volume":"374","author":"Yazici","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD008341-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/BOR.0b013e3280126b66","article-title":"Work disability in rheumatic diseases","volume":"19","author":"Yelin","year":"2007","journal-title":"Curr Opin Rheumatol"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:18:03Z","timestamp":1777317483000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008341"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008341","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}